托法替布治疗银屑病关节炎后血脂变化与心血管事件发生率:III期及长期延展研究汇总分析
该汇总分析纳入783例接受托法替布5 mg或10 mg每日两次联合传统合成改善病情抗风湿药治疗的活动性银屑病关节炎患者,评估空腹血脂、血压、高血压相关不良事件及主要不良心血管事件(MACE)。结果显示治疗3个月和6个月时LDL-c与HDL-c较基线升高9%至14%,LDL-c:HDL-c及总胆固醇:HDL-c比值无有意义变化,血压24个月内保持稳定,高血压相关不良事件与MACE发生率均较低。
要点
- 托法替布治疗3个月和6个月时LDL-c与HDL-c较基线升高9%至14%,但LDL-c:HDL-c及总胆固醇:HDL-c比值无有意义变化。
- MACE共5例(0.6%),发生率低,其中2例致死,长期随访仍在进行。
核心结论
- 银屑病关节炎患者接受托法替布治疗后第3个月血脂升高,与类风湿关节炎和银屑病中的观察一致;高血压相关不良事件与MACE发生率均较低,长期随访仍在进行。
研究设计与样本
- 汇总2项III期研究(OPAL Broaden、OPAL Beyond)和1项正在进行的长期延展研究(OPAL Balance,数据截止2017年1月,数据库未锁定)的数据。
- 共纳入783例接受托法替布5 mg或10 mg每日两次联合传统合成改善病情抗风湿药治疗的活动性银屑病关节炎患者。
- 评估指标包括空腹血脂水平、血压、高血压相关不良事件(含高血压、血压升高)及MACE。
主要发现
- 托法替布5 mg和10 mg组在3个月和6个月时LDL-c与HDL-c较基线的升高幅度为9%至14%。
- 未观察到LDL-c:HDL-c或总胆固醇:HDL-c比值的有意义变化。
- 血压在24个月内保持稳定。
- 5例患者(0.6%)发生MACE,发生率每100患者年为0.24(95%CI 0.05-0.70),其中2例致死。
关键数值与推荐
- LDL-c与HDL-c较基线升高幅度:托法替布5 mg和10 mg组在3个月和6个月时为9%至14%。
- MACE:5例(0.6%),发生率每100患者年0.24(95%CI 0.05-0.70),其中2例致死。
临床怎么用
- 银屑病关节炎患者使用托法替布治疗时应关注第3个月起的血脂变化,但LDL-c:HDL-c及总胆固醇:HDL-c比值未见有意义变化。
- 治疗期间血压在24个月内保持稳定,高血压相关不良事件与MACE发生率低,可据此进行心血管风险监测与患者沟通。
- 长期心血管安全性数据仍在随访中,临床决策需结合个体心血管风险因素综合评估。
局限性
- 数据来自汇总分析,长期延展研究数据库未锁定,长期随访结果尚未完善。
- 摘要未报告对照组的血脂与心血管事件比较数据,无法直接比较托法替布与对照组的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The risk of cardiovascular disease (CVD) is higher in patients with psoriatic arthritis (PsA) compared to the general population. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Because tofacitinib increases circulating lipid levels in some patients, we evaluated CVD risk factors and major adverse cardiovascular events (MACE) in patients with active PsA receiving tofacitinib 5 or 10 mg twice daily plus conventional synthetic disease-modifying antirheumatic drugs. METHODS: Data were pooled from 2 phase III studies (Efficacy and Safety of Tofacitinib in Psoriatic Arthritis [OPAL Broaden] and Tofacitinib in Patients with Psoriatic Arthritis With Inadequate Response to TNF Inhibitors [OPAL Beyond]) and 1 ongoing long-term extension (Open-Label Extension Study of Tofacitinib in Psoriatic Arthritis [OPAL Balance], data cutoff January 2017; database not locked). Outcomes included fasting lipid levels, blood pressure, hypertension-related adverse events (AEs; including hypertension, high blood pressure, and increased blood pressure), and MACE. RESULTS: Overall, 783 tofacitinib-treated patients were included. Percentage increases from baseline in low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) levels ranged from 9% to 14% for tofacitinib 5 mg and 10 mg at 3 and 6 months; no meaningful changes in LDL-c:HDL-c or total cholesterol:HDL-c ratios were observed. Blood pressure remained stable for 24 months. Fifty-eight patients (7.4%) had hypertension-related AEs; none were fatal (incidence rate [IR] per 100 patient-years 4.81 [95% confidence interval (95% CI) 3.65-6.22]). Five patients (0.6%) had MACE (IR 0.24 [95% CI 0.05-0.70]); 2 were fatal. CONCLUSION: Serum lipid level increases at month 3 following tofacitinib treatment in PsA were consistent with observations in rheumatoid arthritis and psoriasis. The IR of hypertension-related AEs and MACE was low; long-term follow-up is ongoing.
引用
- Gladman DD, Charles-Schoeman C, McInnes IB, et al. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. Arthritis Care Res (Hoboken). 2019. PMID: 31112005. doi:10.1002/acr.23930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。